As of now, India not for WTO dispute body on drug row with EU

Image
Press Trust of India New Delhi
Last Updated : Jan 21 2013 | 6:21 AM IST

On an indication that the drug seizure dispute with the European Union (EU) would be resolved, has not sought setting up of a settlement body in the World Trade Organisation, Parliament was informed today.

"As EU has indicated to resolve the dispute, India has not yet sought establishment of a (settlement) panel in this dispute," Minister of State for Commerce and Industry Jyotiraditya Scindia said in a written reply to a question in Lok Sabha.

He said, the consultations with the EU are continuing. India and Brazil had approached the WTO in May this year against the alleged illegal detention of Indian generic medicines while in transit through the EU ports.

Scindia said since then, consultations have been held with the EU. Once a country seeks a redressal from the WTO against another country, the multilateral body asks the parties in the dispute to hold formal consultations. The matter is referred to the Dispute Settlement Body (DSB) in case these consultations do not yield satisfactory results.

Some countries in EU had seized Indian drugs alleging that they violated their patent laws. The Indian side has been maintaining that these are off patent medicines.

"Consultations have been very useful, as EU has acknowledged that some provisions of the relevant EC (European Commission) regulation may have been misinterpreted by the Customs authorities of EU...(It) has shown willingness to resolve the dispute without the need to seek establishment of a panel" he said.

In a separate reply, the minister said that in order to "provide remedy to the domestic industry against dumped imports causing material injury," the Directorate General of Anti Dumping and Allied Duties has recommended imposition of a levy on imports of a large number of chemicals. These include caustic soda, titanium dioxide, melamine and saccharin.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 15 2010 | 5:44 PM IST

Next Story